These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35948476)

  • 1. Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
    Deng JH; Zhong GW; Zhang JX
    Ann Palliat Med; 2022 Aug; 11(8):2789-2791. PubMed ID: 35948476
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
    Kawada T
    Arthritis Rheumatol; 2023 Sep; 75(9):1680-1681. PubMed ID: 36908047
    [No Abstract]   [Full Text] [Related]  

  • 4. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
    Becker MA; MacDonald PA; Hunt B; Gunawardhana L
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
    Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia.
    Xu C; Meng J
    Int J Cardiol; 2023 Jan; 370():367. PubMed ID: 36306952
    [No Abstract]   [Full Text] [Related]  

  • 14. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
    Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
    Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.